Aurinia Pharmaceuticals (NasdaqGM:AUPH) Valuation in Focus After Strong Share Price Gains and Growth Surge
Aurinia Pharmaceuticals (AUPH) shares have swung higher over the past three months, gaining around 28%. Investors are taking notice of the strong upward momentum, especially after the company’s recent annual revenue and net income growth.
See our latest analysis for Aurinia Pharmaceuticals.
After a robust stretch where Aurinia Pharmaceuticals booked double-digit revenue and income growth, the shares are still showing impressive energy. The latest rally capped off a 90-day share price return of 28%, helping the company achieve a total shareholder return of 59% over the past year. This kind of momentum suggests that investors are warming up to the story and may see more potential ahead.
If Aurinia’s run-up has you interested in what…
